JP2020500193A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500193A5 JP2020500193A5 JP2019526314A JP2019526314A JP2020500193A5 JP 2020500193 A5 JP2020500193 A5 JP 2020500193A5 JP 2019526314 A JP2019526314 A JP 2019526314A JP 2019526314 A JP2019526314 A JP 2019526314A JP 2020500193 A5 JP2020500193 A5 JP 2020500193A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- acid
- deuterated
- compound
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 17
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims 8
- 229960004488 linolenic acid Drugs 0.000 claims 7
- 150000002148 esters Chemical class 0.000 claims 5
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims 4
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 4
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 4
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 4
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims 4
- 229940033080 omega-6 fatty acid Drugs 0.000 claims 4
- 150000007970 thio esters Chemical class 0.000 claims 3
- KFINXCASWPGHEW-UHFFFAOYSA-N (9S*,10R*,11R*,12Z,15Z)-9,10,11-trihydroxyoctadeca-12,15-dienoic acid Natural products CCC=CCC=CC(O)C(O)C(O)CCCCCCCC(O)=O KFINXCASWPGHEW-UHFFFAOYSA-N 0.000 claims 2
- OYHQOLUKZRVURQ-ZVDPVMROSA-N (9z,12z)-11,11-dideuteriooctadeca-9,12-dienoic acid Chemical compound CCCCC\C=C/C([2H])([2H])\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-ZVDPVMROSA-N 0.000 claims 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- MZQXAWAWDWCIKG-SPSBLGDNSA-N Avenoleic acid Chemical compound CCC[C@@H](O)C\C=C/C\C=C/CCCCCCCC(O)=O MZQXAWAWDWCIKG-SPSBLGDNSA-N 0.000 claims 2
- 102000009645 Mitochondrial Aldehyde Dehydrogenase Human genes 0.000 claims 2
- 108010009513 Mitochondrial Aldehyde Dehydrogenase Proteins 0.000 claims 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 235000006708 antioxidants Nutrition 0.000 claims 2
- FPRKGXIOSIUDSE-SYACGTDESA-N (2z,4z,6z,8z)-docosa-2,4,6,8-tetraenoic acid Chemical class CCCCCCCCCCCCC\C=C/C=C\C=C/C=C\C(O)=O FPRKGXIOSIUDSE-SYACGTDESA-N 0.000 claims 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 claims 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 229930003268 Vitamin C Natural products 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 235000021342 arachidonic acid Nutrition 0.000 claims 1
- 229940114079 arachidonic acid Drugs 0.000 claims 1
- 235000017471 coenzyme Q10 Nutrition 0.000 claims 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical group COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 1
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 150000002194 fatty esters Chemical class 0.000 claims 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 claims 1
- 229960004135 idebenone Drugs 0.000 claims 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 235000019154 vitamin C Nutrition 0.000 claims 1
- 239000011718 vitamin C Substances 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022130995A JP7464661B2 (ja) | 2016-11-17 | 2022-08-19 | 同位体修飾成分及びその治療上の使用 |
| JP2024052901A JP2024081733A (ja) | 2016-11-17 | 2024-03-28 | 同位体修飾成分及びその治療上の使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423699P | 2016-11-17 | 2016-11-17 | |
| US62/423,699 | 2016-11-17 | ||
| PCT/US2017/062107 WO2018094116A1 (en) | 2016-11-17 | 2017-11-16 | Isotopically modified components and therapeutic uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022130995A Division JP7464661B2 (ja) | 2016-11-17 | 2022-08-19 | 同位体修飾成分及びその治療上の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020500193A JP2020500193A (ja) | 2020-01-09 |
| JP2020500193A5 true JP2020500193A5 (enExample) | 2020-12-17 |
| JP7132630B2 JP7132630B2 (ja) | 2022-09-07 |
Family
ID=62145748
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019526314A Active JP7132630B2 (ja) | 2016-11-17 | 2017-11-16 | 同位体修飾成分及びその治療上の使用 |
| JP2022130995A Active JP7464661B2 (ja) | 2016-11-17 | 2022-08-19 | 同位体修飾成分及びその治療上の使用 |
| JP2024052901A Pending JP2024081733A (ja) | 2016-11-17 | 2024-03-28 | 同位体修飾成分及びその治療上の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022130995A Active JP7464661B2 (ja) | 2016-11-17 | 2022-08-19 | 同位体修飾成分及びその治療上の使用 |
| JP2024052901A Pending JP2024081733A (ja) | 2016-11-17 | 2024-03-28 | 同位体修飾成分及びその治療上の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11166930B2 (enExample) |
| JP (3) | JP7132630B2 (enExample) |
| KR (1) | KR102580606B1 (enExample) |
| CN (1) | CN110167546A (enExample) |
| AU (2) | AU2017363147B2 (enExample) |
| WO (1) | WO2018094116A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010313249B2 (en) * | 2009-10-30 | 2016-05-19 | Biojiva Llc | Alleviating oxidative stress disorders with PUFA derivatives |
| WO2018094116A1 (en) | 2016-11-17 | 2018-05-24 | Retrotope, Inc. | Isotopically modified components and therapeutic uses thereof |
| EP3781150A4 (en) * | 2018-04-20 | 2022-01-05 | Retrotope, Inc. | STABILIZED POLYUNSATURATED COMPOUNDS AND THEIR USES |
| CN109601803A (zh) * | 2018-11-07 | 2019-04-12 | 江西颐迪科技有限公司 | 一种能消除老年人体味并有助健康的饮料及其制作方法 |
| US20220009950A1 (en) * | 2018-11-15 | 2022-01-13 | Retrotope, Inc. | Deuterated compounds, compositions, and methods of use |
| WO2020206350A1 (en) * | 2019-04-04 | 2020-10-08 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting gene expression in the central nervous system |
| EP4103145A4 (en) * | 2020-02-12 | 2024-07-03 | Retrotope, Inc. | DEUTERATED POLYUNSATURATED FATTY ACIDS OR THEIR ESTERS FOR COSMETIC APPLICATIONS |
| CA3171330A1 (en) * | 2020-02-14 | 2021-08-19 | Retrotope, Inc. | Methods for treating tauopathy |
| US11510889B2 (en) | 2021-02-05 | 2022-11-29 | Retrotope, Inc. | Methods for inhibiting the progression of neurodegenerative diseases |
| US12109194B2 (en) | 2021-02-05 | 2024-10-08 | Biojiva Llc | Synergistic combination therapy for treating ALS |
| US11491130B2 (en) | 2021-02-05 | 2022-11-08 | Retrotope, Inc. | Methods of treating amyotrophic lateral sclerosis |
| US11351143B1 (en) * | 2021-02-05 | 2022-06-07 | Retrotope, Inc. | Methods of treating amyotrophic lateral sclerosis |
| CA3210776A1 (en) * | 2021-02-05 | 2022-08-11 | Retrotope, Inc. | Methods for assessing a patient's response to treatment of a neurodegenerative disease with deuterated arachidonic acid |
| WO2023122195A2 (en) * | 2021-12-21 | 2023-06-29 | Biojiva Llc | Anti-inflammatory methods with compositions comprising site-specific isotopically-modified fatty acids |
| WO2023158641A1 (en) * | 2022-02-15 | 2023-08-24 | Retrotope, Inc. | Synergistic combination therapy for treating als |
| CN120435548A (zh) * | 2022-12-01 | 2025-08-05 | 匹克生物酶高科技有限公司 | 用于解毒内源醛类的食品和药物组合物 |
| KR20250110548A (ko) | 2024-01-12 | 2025-07-21 | 현대모비스 주식회사 | 전기자동차용 배터리팩 케이스 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6331532B1 (en) | 1998-11-25 | 2001-12-18 | University Of Otago | Mitochondrially targeted antioxidants |
| US20030069208A1 (en) | 1997-11-25 | 2003-04-10 | University Of Otago | Mitochondrially targeted antioxidants |
| WO2000006143A1 (en) * | 1998-07-27 | 2000-02-10 | Texas Pharmaceuticals, Inc. | Chemically induced intracellular hyperthermia |
| US20060229278A1 (en) | 1998-11-25 | 2006-10-12 | Antipodean Pharmaceuticals, Inc. | Mitoquinone derivatives used as mitochondrially targeted antioxidants |
| US20080275005A1 (en) | 1998-11-25 | 2008-11-06 | Murphy Michael P | Mitochondrially targeted antioxidants |
| US20070270381A1 (en) | 2000-05-25 | 2007-11-22 | Antipodean Pharmaceuticals, Inc. | Mitochondrially targeted antioxidants |
| US6544764B2 (en) * | 2000-11-14 | 2003-04-08 | Applera Corporation | Isolated human dehydrogenase proteins, nucleic acid molecules encoding these human dehydrogenase proteins, and uses thereof |
| US20030032078A1 (en) * | 2001-01-23 | 2003-02-13 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of macular and retinal degenerations |
| NZ513547A (en) | 2001-08-13 | 2002-09-27 | Antipodean Biotechnology Ltd | Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone) |
| US7888334B2 (en) | 2003-08-22 | 2011-02-15 | Antipodean Pharmaceuticals, Inc. | Mitoquinone derivatives used as mitochondrially targeted antioxidants |
| CN1839142B (zh) | 2003-08-22 | 2010-06-16 | 澳新制药公司 | 用作靶向线粒体的抗氧化剂的线粒体醌衍生物 |
| CA2580584C (en) | 2003-09-19 | 2015-07-28 | Galileo Pharmaceuticals, Inc. | Use of alpha-tocotrienol for treatment of mitochondrial diseases |
| DK1909600T3 (da) * | 2005-07-29 | 2012-07-30 | Tima Foundation | Sammensætning til moderering af alkoholmetabolisme og til at reducere risikoen for alkoholforårsagede sygdomme |
| ES2823728T3 (es) | 2005-09-15 | 2021-05-10 | Ptc Therapeutics Inc | Variantes de cola de agentes terapéuticos con actividad redox para el tratamiento de enfermedades mitocondriales y otras afecciones y la modulación de biomarcadores de energía |
| CA2708961C (en) | 2008-01-08 | 2017-03-28 | Ptc Therapeutics, Inc. | (het)aryl-p-quinone derivatives for treatment of mitochondrial diseases |
| WO2009145982A1 (en) | 2008-04-01 | 2009-12-03 | Antipodean Pharmaceuticals, Inc. | Compositions and methods for skin care |
| US8124389B2 (en) * | 2008-05-07 | 2012-02-28 | The Board Of Trustees Of The Leland Stanford Junior University | Crystal structure of aldehyde dehydrogenase and methods of use thereof |
| US20100029706A1 (en) | 2008-07-30 | 2010-02-04 | Edison Parmaceuticals, Inc. a Delaware Corporation | HYDROGENATED PYRIDO[4,3-b]INDOLES FOR THE TREATMENT OF OXIDATIVE STRESS |
| AU2010313249B2 (en) | 2009-10-30 | 2016-05-19 | Biojiva Llc | Alleviating oxidative stress disorders with PUFA derivatives |
| US20120005765A1 (en) * | 2010-07-01 | 2012-01-05 | Saint Louis University | Animal model for parkinson's disease |
| CA2860453C (en) * | 2011-01-24 | 2020-04-28 | Inceptum Research & Therapeutics, Inc. | Compositions comprising a prostaglandin for treating neuropsychiatric conditions |
| KR102110200B1 (ko) * | 2011-04-26 | 2020-05-13 | 레트로토프 인코포레이티드 | 산화성 망막 질환 |
| JP6145087B2 (ja) * | 2011-04-26 | 2017-06-07 | レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． | Ｐｕｆａ酸化関与障害 |
| KR102020611B1 (ko) * | 2011-04-26 | 2019-09-10 | 레트로토프 인코포레이티드 | Ｐｕｆａ와 관련된 신경퇴행성 질환 및 근육 질환 |
| WO2018094116A1 (en) | 2016-11-17 | 2018-05-24 | Retrotope, Inc. | Isotopically modified components and therapeutic uses thereof |
-
2017
- 2017-11-16 WO PCT/US2017/062107 patent/WO2018094116A1/en not_active Ceased
- 2017-11-16 CN CN201780078162.9A patent/CN110167546A/zh active Pending
- 2017-11-16 KR KR1020197017162A patent/KR102580606B1/ko active Active
- 2017-11-16 US US16/348,087 patent/US11166930B2/en active Active
- 2017-11-16 JP JP2019526314A patent/JP7132630B2/ja active Active
- 2017-11-16 AU AU2017363147A patent/AU2017363147B2/en active Active
-
2021
- 2021-10-27 US US17/512,531 patent/US20220133668A1/en not_active Abandoned
-
2022
- 2022-08-19 JP JP2022130995A patent/JP7464661B2/ja active Active
-
2023
- 2023-12-14 AU AU2023282263A patent/AU2023282263A1/en not_active Abandoned
-
2024
- 2024-03-28 JP JP2024052901A patent/JP2024081733A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Singh et al. | Microbial production of docosahexaenoic acid (DHA, C22: 6) | |
| Schunck et al. | Therapeutic potential of omega-3 fatty acid-derived epoxyeicosanoids in cardiovascular and inflammatory diseases | |
| Vanden Heuvel | Nutrigenomics and nutrigenetics of ω3 polyunsaturated fatty acids | |
| Poorani et al. | COX-2, aspirin and metabolism of arachidonic, eicosapentaenoic and docosahexaenoic acids and their physiological and clinical significance | |
| Calder | Fatty acids and inflammation: the cutting edge between food and pharma | |
| Konkel et al. | Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids | |
| JP2014512351A5 (enExample) | ||
| Kaur et al. | Essential fatty acids as functional components of foods-a review | |
| Martínez-Fernández et al. | Omega-3 fatty acids and adipose tissue function in obesity and metabolic syndrome | |
| Calder | Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases | |
| Yates et al. | Pharmacology and therapeutics of omega-3 polyunsaturated fatty acids in chronic inflammatory disease | |
| Wall et al. | Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids | |
| Betancor et al. | Influence of dietary docosahexaenoic acid in combination with other long-chain polyunsaturated fatty acids on expression of biosynthesis genes and phospholipid fatty acid compositions in tissues of post-smolt Atlantic salmon (Salmo salar) | |
| Weylandt | Docosapentaenoic acid derived metabolites and mediators–the new world of lipid mediator medicine in a nutshell | |
| Panda et al. | PUFA, genotypes and risk for cardiovascular disease | |
| HRP20200068T1 (hr) | Etilni ester ikozapentaenske kiseline, namijenjen liječenju hipertrigliceridemije | |
| IN2014DN08089A (enExample) | ||
| JP2012516852A5 (enExample) | ||
| JP2018168170A5 (enExample) | ||
| JP2015527386A5 (enExample) | ||
| JP2015500639A5 (enExample) | ||
| JP2011529503A5 (enExample) | ||
| JP2007504225A5 (enExample) | ||
| WO2008147562A3 (en) | Dietary formulations and methods for treatment of inflammation and other disorders | |
| JP2016501248A5 (enExample) |